Skip to main content
. 2022 May 9;13:2522. doi: 10.1038/s41467-022-30240-8

Fig. 5. Microbiota-derived butyrate gavage delays AML progression.

Fig. 5

a Schematic diagram of the mouse experimental process, including butyrate gavage. b Photographs of spleens from butyrate-treated AML mice (n = 5) and control AML mice (n = 5). c Leukaemia cells (GFP+ cells) in the bone marrow, peripheral blood, and spleen from butyrate-treated AML mice (n = 5) and control AML mice (n = 5). Details of the gating strategy are described in Supplementary Fig. 11b. d HE histopathology sections and Ki67 immunohistochemical staining of a representative spleen in butyrate-treated and control AML mice. All microscopic analyses were performed at an original magnification of ×80 or ×200, scale bar = 1000 and 275 µm. e Kaplan–Meier survival curve of AML mice (n = 5 per group). f On 8 and 14 days after injection of MLL-AF9 cells, the load of Luc-expressing MLL-AF9 cells in mice was analysed by IVIS (n = 3 per group). P values were determined using unpaired two-tailed t-test and error bars represent mean ± SEM in b, c, f. P values were determined Gehan–Breslow–Wilcoxon test and error bars represent mean ± SEM in e. ***P < 0.0001 (b), ***P < 0.0001 PB, **P = 0.0066 SP, ***P = 0.0006 BM (c), *P = 0.0137 (f), **P = 0.0026 (e). Source data are provided as a Source Data file.